Description of the Report
Myocardial Infarction, also known as heart attack, is a medical term. Heart attack is a severe condition where blood flow to the heart muscle is disrupted suddenly, causing tissue destruction. A blockage of one or more coronary vessels is the most common cause. Plaque buildup can cause a blockage. This is mainly made up of cholesterol, fat, and other cellular waste products.
Myocardial Infarction symptoms include pain in the chest, nausea, vomiting, and heartburn. Risk factors such as age, smoking, diabetes, high blood pressure, obesity, and illicit drug use can lead to the unintentional buildup of fat deposits (atherosclerosis). This narrows the arteries in the body, which may cause a heart attack.
Heart attack can be treated with medications such as antiplatelet agents, pain relievers, and aspirin. Heart attack can also be treated with procedures like stenting and coronary angioplasty. This procedure involves a long, thin tube (catheter) inserted through the wrist into the blocked artery of the heart. A coronary bypass procedure may be necessary to restore blood supply to the heart muscle.
Global Myocardial Infarction Market (COVID-19), Impact of the Coronavirus
The first reports of the COVID-19 pandemic were made in Wuhan, China, on December 31, 2019. On March 11, 2020, the World Health Organization declared COVID-19 a pandemic. The Coronavirus (COVID-19), Weekly Epidemiological Updating by the World Health Organization, reported more than 182 million cases of COVID-19 and 3.95 million deaths worldwide between March 11, 2020, and July 2, 2021.
The Impact of COVID-19 On Demand and Supply for Myocardial Infarction Treatment
Businesses in all sectors, including the private healthcare sector, have been affected by the COVID-19 pandemic and the lockdown in several countries around the world. Due to tight lockdown in many regions, the COVID-19 pandemic impacted all aspects of the healthcare supply chain. The economy of different areas around the world has been affected by the COVID-19 pandemic in three ways. It first directly affects production and demand, then it disrupts distribution channels. Finally, it impacts financial markets and companies. Many countries, including Singapore, Thailand, Indonesia, and Indonesia, have difficulties with the transportation and distribution of healthcare products. The COVID-19 pandemic in 2020 caused worldwide disruptions to healthcare delivery, including delays in diagnosing and treating cardiovascular diseases. The global market for myocardial injury is likely to slow down due to the impact of the COVID-19 pandemic. According to a news article in the American College of Cardiology, 909 outpatient and inpatient cardiac diagnostic centers performed procedures in 108 countries. It was reported that during the pandemic, cardiac diagnostic. Procedure’s figures fell by 42% between March 2019 and March 2020 and 64%between March 2019 and April 2020. Transthoracic echocardiography declined by 59%, transesophageal echocardiography fell by 76%, stress tests decreased by 78%, and transthoracic echocardiography by 59%.
The increase in heart disease following the COVID-19 vaccine is expected to drive the global myocardial injury market’s growth over the forecast period. According to the Centers for Disease Control and Prevention, since April 2021, thousands have been reported to the Vaccine Adverse Event Reporting Systems (VAERS). These cases were caused by the mRNA COVID-19 vaccine (i.e., Pfizer-BioNTech Moderna).
The global myocardial injury market value will be US$ 1,816.8 Million in 2021. It is expected to grow at a CAGR in the forecast period (2021-2028).
- Growth drivers: Heart attack cases are on the rise
- Product launches and approvals are on the rise
- Market players are increasing their research and development activities
Figure 1 – Global Myocardial Injury Market Share (%) Analysis by Drug Class, 2021
The growth of the global market for myocardial ischemia is expected to be driven by the prevalence of heart attacks.
The global myocardial Infarction Market is expected to grow due to increasing heart attack rates. According to the Centers for Disease Control and Prevention report 2019, approximately 805,000 Americans suffer from a heart attack each year in the United States. Six hundred five thousand are first-time cases, 200,000 are repeated heart attacks, and one-fifth of heart attacks are silent.
Research and Development activities
The growth of the global market for myocardial ischemia is expected to be aided by the increasing number of clinical trials being conducted to treat castrate-resistant prostate cancer. Recardio Inc. is a clinical-stage company that focuses on regenerative therapies for cardiovascular diseases. In May 2021, it completed Phase 2 of a randomized, double-blind, and placebo-controlled safety and efficacy study using dutogliptin with filgrastim for early recovery after myocardial Infarction.
Global Myocardial Infarction Market Regional Analysis
The global market for myocardial injury is divided by region into North America and Latin America, Europe, Asia Pacific Middle East, Asia Pacific, Middle East, and Africa.
Due to product launches and approvals, North America will continue to dominate the global myocardial-infarction market. AstraZeneca plc., an American-Swedish multinational biotech and pharmaceutical company, was granted Fast Track Designation in America on July 16, 2020, for Farxiga (dapagliflozin). This product will reduce the risk of hospitalization for heart disease (H.F.) and cardiovascular death (CV) in adults following an acute myocardial injury (MI) or heart attack.
Europe will see a significant increase in myocardial-infarction sales over the forecast period due to product approvals from European regulatory agencies to treat heart disease. Sanofi S.A., a global pharmaceutical company that focuses on human health, announced in February 2021 that Plavix (clopidogrel) was approved by the European Commission for adult patients suffering from moderate to high-risk Transient Ischemic Attacks (T.I.A.) or minor Ischemic Strokes (I.S.) within 24 hours of the TIA/IS the event. This new indication allows for a 21-day test followed by long-term single-anti-platelet therapy.
Global Myocardial Infarction Market Competition
Bristol-Myers Squibb Co. and Bayer AG dominate the market for myocardial injury. Johnson & Johnson Services Inc. Sanofi S.A. Novartis International AG. AstraZeneca plc. Daiichi Sankyo Co Ltd. Boehringer Ingelheim International GmbH. Merck KGaA. is some of the major players.
Myocardial Infarction, also known as heart attack, is called myocardial Infarction. A heart attack is when one of the coronary vessels of the heart becomes blocked suddenly or has prolonged blood flow.
A blood clot (or thrombus) is the most common reason for the sudden blockage of a coronary vessel. A blood clot forms in a narrowed coronary artery. This is caused by fatty deposits (plaques), which accumulate along the artery’s inner wall.
Heart attack symptoms include chest discomfort, pain in the upper body, anxiety, shortness or no breath, anxiety, dizziness, extreme weakness, chest discomfort, and sweating. To diagnose a heart attack, E.C.G. and blood tests will be performed. Heart attack can be treated with drugs such as beta-blockers, aspirin, and vasodilators.
Market players and nonprofit organizations are focusing on heart attack initiatives, which will contribute to the global myocardial Infarction market growth during the forecast period. The American College of Cardiology (A.C.C.), a medical association not for profit, announced its It revealed that it had The Global Heart Attack Treatment Initiative (GHATI) had measurable positive impacts on delivering heart attack care in low- and middle-income countries. This initiative was established in 2019 to improve heart attack outcomes in low- and middle-income countries. It encourages adherence to guidelines-based medical therapy.
Market players are now focusing on product launches, strengthening their position within the global myocardial injury market. AstraZeneca plc. announced on June 1, 2020, that Brilinta (ticagrelor), its drug, has been approved by the U.S. Food and Drug Administration. This approval is to lower the risk of a stroke or heart attack in high-risk patients who have coronary artery disease (CAD), which is the most common type.
Market players and government agencies are actively involved in growing their global presence through strategies such as acquisitions or partnerships. This is expected to help drive growth in the global myocardial Infarction market. Amgen Inc., a multinational biotechnology company, announced on October 4, 2020, a new partnership with two U.K. National Health Service (N.H.S.), organizations: the North West Coast Innovation Agency and Imperial College Health Partners. This collaboration will help fight the silent killer of high cholesterol on the North West Coast, which is plagued by heart attacks and strokes, and premature death from cardiovascular diseases.
The study’s key features are:
- This report gives an in-depth analysis of the global market for myocardial ischemia. It also provides market size (US$ million) and compound annual growth rate(CAGR %) for 2021-2028, with 2020 being the base year.
- It clarifies the potential revenue opportunities in different segments and provides an attractive investment proposition matrix.
- The study provides important insights into market drivers, restrictions, opportunities, new product launches and approvals, regional outlook, and competitive strategies used by the top players.
- The following criteria are used to profile the top players in the global market for myocardial injury: Company overview, financial performance, and product portfolio. Geographic presence. Distribution strategies. Key developments and strategies. Plans.
- This study covered vital companies such as Bristol-Myers Squibb Co. and Bayer AG. Johnson & Johnson Services Inc. Sanofi S.A. Novartis International AG. AstraZeneca plc. Daiichi Sankyo Co Ltd. Boehringer Ingelheim International GmbH., Merck KGaA.
- This report will provide insight for marketers and management to help them make informed decisions about product launches, technology upgrades, market expansion, and marketing strategies.
- Global myocardial Infarction Market Report is for investors, distributors, financial analysts, financiers, and suppliers.
- Through the use of different strategy matrices in analyzing the global market for myocardial injury, stakeholders would be able to make better decisions.
Myocardial Infarction Market Report Scope and Segmentation
|UNIT||Value (USD Million/Billion)|
|BY REGION||North America, Europe, Asia Pacific, Latin America, Middle East and Africa|
- Global Myocardial Infarction Market by Drug Class
- Antiplatelet Agents
- Glycoprotein IIb/IIIa Inhibitors
- Antithrombotic Agents
- Beta-adrenergic blockers
- Angiotensin-converting Enzyme (A.C.E.) Inhibitors
- Angiotensin receptor Blockers
- Global Myocardial Infarction Market by Route of Administration
- Global Myocardial Infarction Market by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Company Profiles
- Bristol-Myers Squibb Co
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Bayer AG
- Johnson & Johnson Services Inc.
- Sanofi S.A.
- Novartis International AG
- AstraZeneca plc.
- Daiichi Sankyo Co Ltd
- Boehringer Ingelheim International GmbH
- Pfizer Inc.
- Merck KGaA.
- North America
- The Netherlands
- Czech Republic
- Rest of Europe
- Asia Pacific
- South Korea
- Australia & New Zealand
- Rest of Asia Pacific
- South America
- Rest of South America
- The Middle East & Africa
- Saudi Arabia
- South Africa
- Northern Africa
- Rest of MEA